Results 51 to 60 of about 41,661 (291)

Androgen Deprivation Therapy in High-Risk Localized and Locally Advanced Prostate Cancer

, 2022
The recommended treatment for high-risk localized or locally advanced prostate cancer is radical prostatectomy plus extended pelvic lymph node dissection or radiation therapy plus long-term androgen deprivation therapy. However, some patients are treated
Hiroaki Iwamoto, Tomoyuki Makino, Kouji Izumi, Atsushi Mizokami   +3 more
core   +1 more source

A Fully Human Engineered Bone Niche With Endogenous Osteoclastogenesis Reveals Osteoclast‐Dependent Osteomimicry in Prostate Cancer Cells

Advanced Healthcare Materials, EarlyView.
A human 3D bone niche integrating osteoblasts and osteoclasts enables co‐culture with prostate cancer cell lines and patient‐derived organoids. The engineered niche (i) models aspects of reciprocal phenotypic regulation between osteoblasts and cancer cells, (ii) captures osteoclast‐enhanced osteomimicry in tumor cells, and (iii) establishes a ...
Andrea Mazzoleni, Robin Dolgos, Thomas Menter, Boris Dasen, Arnaud Scherberich, Clémentine Le Magnen, Manuele G. Muraro, Ivan Martin   +7 more
wiley   +1 more source

Androgen Receptor‐Induced Lactoferrin Accelerates Prostate Tumorigenesis Through Modulating Ferroptosis

Advanced Science, EarlyView.
This study demonstrates that transcription factor androgen receptor (AR) directly binds the LF promoter, driving lactoferrin overexpression to promote ferritin (FTH1/FTL) upregulation and inhibit p53‐ALOX12‐mediated ferroptosis in prostate cancer. Lactoferrin could be a new potential therapeutic target in prostate cancer.
Can Liu, Qiu Peng, Xiaoyue Zhang, Zhengshuo Li, Yangge Wu, Yuqing Wen, Run Zheng, Shuanglong Wu, Chenfei Zhou, Zhengyu Hu, Lanjun Shu, Xinyi Ma, Qiuyang Li, Ya Ma, Chunlin Ou, Ming Zhao, Songqing Fan, Lingyu Wei, Jian Ma   +18 more
wiley   +1 more source

Androgen Receptor Signaling in the Development of Castration-Resistant Prostate Cancer

Frontiers in Oncology, 2019
Most prostate cancers are androgen-sensitive malignancies whose growths depend on the transcriptional activity of the androgen receptor (AR). In the 1940s, Charles Huggins demonstrated that the surgical removal of testes in men can result in a dramatic ...
Qin Feng, Bin He, Bin He
doaj   +1 more source

The androgen receptor is a therapeutic target in desmoplastic small round cell sarcoma

Nature Communications, 2022
Androgen receptor can promote tumour progression in desmoplastic small round cell tumour (DSRCT), an aggressive paediatric malignancy that predominantly affects young males.
Salah-Eddine Lamhamedi-Cherradi, Mayinuer Maitituoheti, Brian A. Menegaz, Sandhya Krishnan, Amelia M. Vetter, Pamela Camacho, Chia-Chin Wu, Hannah C. Beird, Robert W. Porter, Davis R. Ingram, Vandhana Ramamoorthy, Sana Mohiuddin, David McCall, Danh D. Truong, Branko Cuglievan, P. Andrew Futreal, Alejandra Ruiz Velasco, Nazanin Esmaeili Anvar, Budi Utama, Mark Titus, Alexander J. Lazar, Wei-Lien Wang, Cristian Rodriguez-Aguayo, Ravin Ratan, J. Andrew Livingston, Kunal Rai, A. Robert MacLeod, Najat C. Daw, Andrea Hayes-Jordan, Joseph A. Ludwig   +29 more
doaj   +1 more source

A synthetic lethal screen for Snail-induced enzalutamide resistance identifies JAK/STAT signaling as a therapeutic vulnerability in prostate cancer

Frontiers in Molecular Biosciences, 2023
Despite substantial improvements in the treatment landscape of prostate cancer, the evolution of hormone therapy-resistant and metastatic prostate cancer remains a major cause of cancer-related death globally.
Kathryn E. Ware, Kathryn E. Ware, Beatrice C. Thomas, Pelumi D. Olawuni, Pelumi D. Olawuni, Maya U. Sheth, Maya U. Sheth, Nathan Hawkey, Nathan Hawkey, M. Yeshwanth, Brian C. Miller, Katherine J. Vietor, Mohit Kumar Jolly, So Young Kim, Andrew J. Armstrong, Andrew J. Armstrong, Andrew J. Armstrong, Jason A. Somarelli, Jason A. Somarelli   +18 more
doaj   +1 more source

Denosumab in men receiving androgen-deprivation therapy for prostate cancer

, 2009
Androgen-deprivation therapy is well-established for treating prostate cancer but is associated with bone loss and an increased risk of fracture. We investigated the effects of denosumab, a fully human monoclonal antibody against receptor activator of ...
Szwedowski, M., Smith, MR, Kupic, A, Tammela, T.L., Saad, F, Denosumab, HALT Prostate Cancer Study Group, Goessl, C, Feldman, R, Tammela, TL, Hernández Toriz, N., Ke, C, Szwedowski, M, Goessl, C., Leder, B.Z., Heracek, J, Kupic, A., Ke, C., Egerdie, B., Heracek, J., Leder, BZ, Hernández Toriz, N, Egerdie, B, Saad, F., Feldman, R., Smith, M.R.   +24 more
core   +1 more source

Androgen deprivation therapy and the risk of subsequent keratitis

Tzu Chi Medical Journal, 2021
Objectives: The objective of the study was to determine the risk of subsequent keratitis in prostate cancer (PCa) patients treated with androgen deprivation therapy (ADT). Materials and Methods: Three thousand three hundred and nine patients with PCa were identified using data from ...
Dai-Wei Liu, Ren-Jun Hsu, Sheng-Yao Huang, Yen-Hsiang Liao, Chen-Ta Wu, Wen-Lin Hsu   +5 more
openaire   +3 more sources

T Cell Exhaustion in Cancer Immunotherapy: Heterogeneity, Mechanisms, and Therapeutic Opportunities

Advanced Science, EarlyView.
T cell exhaustion limits immunotherapy efficacy. This article delineates its progression from stem‐like to terminally exhausted states, governed by persistent antigen, transcription factors, epigenetics, and metabolism. It maps the exhaustion landscape in the TME and proposes integrated reversal strategies, providing a translational roadmap to overcome
Yang Yu, Xiaoyu Yao, Qingyang Wang, Mengrui Yang, Runze Li, Jiangjiang Qin, Jing Zhuang, Changgang Sun   +7 more
wiley   +1 more source

Profile of Relugolix in the Management of Advanced Hormone-Sensitive Prostate Cancer: Design, Development, and Place in Therapy

Drug Design, Development and Therapy, 2023
Tomoyuki Tatenuma,1,2 Hiroshi Miyamoto1,3 1Department of Pathology & Laboratory Medicine, University of Rochester Medical Center, Rochester, NY, USA; 2Department of Urology, Yokohama City University Graduate School of Medicine, Yokohama, Japan ...
Tatenuma T, Miyamoto H
doaj